Latest Articlesddd
MOTIF BIO Antibiotic Motif Bio’s (MTFB) antibiotic drug Iclaprim met the Phase 3 Revive-2 trial’s primary endpoints …
Realizing the dream of approval of a small biotech’s lead drug would usually lead a small …
The Week in Review #6 A lot has happened in the past week regarding treatments of …
AstraZeneca’s (AZN) checkpoint PD-L1 inhibitor Imfinzi and NewLink Genetics’ (NLNK) IDO inhibitor indoximod will be combined …
Exelixis (EXEL) announced that Daiichi Sankyo (“Daiichi Sankyo”) reported positive top-line results from a phase 3 …
The Week in Review #5 ALNYLAM (ALNY) and Sanofi Genzyme, the specialty care global business unit …
EXELIXIS Being called overvalued by one analyst does not mean that Exelixis (EXEL) is, indeed, overvalued. …
Prohost Letter #413 FROM BIOTECH TO BIOPHARMA - New research, new findings, new discoveries of trustworthy and …
The Week in Review #4 AMAZING STOCK REBOUNDING - We have already witnessed and wrote about …
Agenus (AGEN) announced that the U.S. Food and Drug Administration (FDA) Advisory Committee voted unanimously, recommending …
Mirati Therapeutics (MRTX) announced positive preliminary data from two ongoing clinical trials of its product sitravatinib …
Following the announcement of two new licensing agreements for its ENHANZE® drug-delivery technology, Halozyme Therapeutics (HALO) raised …
Amicus (FOLD) announced the failure of its topical wound-healing product SD-101 for patients with epidermolysis bullosa …
Positive Phase 2 Results for Tipifarnib in HRAS Mutant Head and Neck Cancer Four of the …
Marinus Pharmaceuticals’ (MRNS) stock rallied following its announcement of top-line data from Phase 2 open-label study …
Indeed, updated data from the ongoing Phase 2 NLG2103 study of NewLink Genetics (NLNK) IDO inhibitor …
In the news, the FDA has placed a clinical hold on two phase 1 trials of …
Portola Portola Pharmaceuticals (PTLA) announced that it will host a webcast and conference call to provide an …
Coming Soon... The Week in Review #3 Gilead Acquisition - Rallying by Association - Improving on …
The answer is, indeed, Gilead (GILD) and its CAR T drug approval will be for non-Hodgkin …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
